Medindia

X

/C O R R E C T I O N -- HealthLeaders-InterStudy/

Friday, December 12, 2008 General News J E 4
Advertisement
In the news release issued by HealthLeaders-InterStudy over PR NewswireDecember 10 with the headline "Downgraded Tier Positions and Step TherapyRestrictions Have Stalled Exforge's and Tekturna's Growth in The HypertensionDrug Market," we are advised by a representative of the company that the pressrelease contained an inaccurate headline and text. The corrected version ofthe press release is below.

Novartis' Exforge and Daiichi-Sankyo's Azor Penetrate Preferred Brand Status

on U.S. Formularies Despite Many Pharmacy Directors' Preference for Using

Individual Drugs Over Fixed-Dose Combinations

Novel Agents Like Novartis' Tekturna Have Also Quickly Gained Preferred BrandTiering Despite Entering a Crowded and Highly Genericized Market, According to

NASHVILLE, Tenn., Dec. 11 /PRNewswire/ -- HealthLeaders-InterStudy, aleading provider of managed care market intelligence, issued an incorrectpress release on December 10 regarding the reimbursement status of Novartis'Exforge and Tekturna hypertension agents. Far from having stalled in gainingfavorable access, these two agents have quickly penetrated Tier 1 and Tier 2in U.S. formularies, with Exforge doubling the percentage of plans placing iton these tiers in just one year, and Tekturna almost tripled the percentage ofplans giving it favored status. Likewise, the percentage of plans reimbursingDaiichi-Sankyo's Azor as a Tier 1 and Tier 2 agent has grown dramatically aswell. The analysis includes a review of tier status of multiple plan typesincluding commercial, employers and pharmacy benefit managers; Medicare andstate Medicaid were excluded.

According to the new Formulary Forum report entitled Formulary Advantagesin Hypertension: Penetration of Advantaged Tiers by Novel Agents and Fixed-Dose Combinations, these gains have come despite reticence on the part ofpharmacy directors to reimburse some of these newer drugs.

"There may be a ceiling that these agents can reach in terms of favorabletier placement," says Jason Labonte, Ph.D., vice president at HealthLeaders-InterStudy. "Forty-four to 67 percent of managed care organization pharmacydirectors surveyed favor use of individual (and often generic) drugs versusthe newer single-pill, fixed-combination brands like Exforge and Azor.However, the past year of gains in favorable reimbursement for these agentscertainly suggests they haven't hit that ceiling yet."

About Formulary Advantages in Hypertension: Penetration of AdvantagedTiers by Novel Agents and Fixed-Dose Combinations

The new Formulary Forum report is based on a survey of 50 pharmacydirectors who control national, regional and state-level managed careorganizations (MCO). Answers were segmented by type of plan to illustratevariances in strategy by size of plan. The easy-to-use PowerPoint formatallows users to cut-and-paste graphs and data into their own presentations.

About Formulary Forum

Formulary Forum is the first and only source for identifying the trends informulary positioning of competing agents, understanding why those trends weretaking place and predicting what changes lay ahead for brand positioning inthe face of both patent expiries and new drug launches. The new report seriesfrom HealthLeaders-InterStudy combines historical formulary data fromFingertip Formulary, which maintains the highest quality and mostcomprehensive, integrated database of formulary information in the UnitedStates, with a robust survey of 50 MCO pharmacy directors. The pharmacydirectors responses reveal what events triggered movement of key brands withintheir formulary for a specific disease as well as what moves they expect tomake in formulary structure as new brands enter the market.

About Fingertip Formulary

Fingertip Formulary (www.FingertipFormulary.com) offers comprehensiveformulary data covering commercial, Medicaid, Medicare and PBM plans, amongothers, in the United States. Fingertip Formulary is a Decision Resources,Inc. company.

About HealthLeaders-InterStudy

HealthLeaders-InterStudy, a Decision Resources, Inc. company, is theauthoritative source for managed care data, analysis and news. For moreinformation, please visit www.HL-ISY.com.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offersbest-in-class, high-value information and insights on important sectors of thehealthcare industry. Clients rely on this analysis and data to make informeddecisions. Both HealthLeaders-InterStudy and Fingertip Formulary are DecisionResources, Inc. companies. Please visit Decision Resources, Inc. atwww.DecisionResourcesInc.com.



------

Downgraded Tier Positions and Step Therapy Restrictions Have Stalled Exforge’s and Tekturna’s Growth in The Hypertension Drug Market

MCO Pharmacy Directors Favor Individual, Generic Drugs Versus Newer Single-Pill Fixed Combination Brands, According to a New Report from HealthLeaders-InterStudy



NASHVILLE, Tenn., Dec. 10 /PRNewswire/ -- HealthLeaders-InterStudy, a leading provider of managed care market intelligence, finds that although Novartis’ Exforge and Tekturna have slowly penetrated tier 2 levels of managed care organization (MCO) formularies over the last 12 months, their progress has stalled. Tekturna has stumbled from having 5.1 percent of U.S. patients accessing the drug at tier 2 in August 2008 to having only 3.9 percent of all patients with access at that same level in November 2008. According to the new Formulary Forum report entitled Formulary Advantages in Hypertension: Penetration of Advantaged Tiers by Novel Agents and Fixed-Dose Combinations, more surveyed MCO pharmacy directors indicate that they have downgraded Exforge’s and Tekturna’s tier position and/or added step therapy restrictions than indicated they had improved tier positioning of the drugs.



“The future reimbursement outlook for repackaging of individual hypertension agents is not that promising,” according to Jason Labonte, Ph.D., vice president at HealthLeaders-InterStudy. “Forty-four to 67 percent of survey respondents favor use of individual (and often generic) drugs versus the newer single-pill, fixed-combination brands like Exforge and Daiichi Sankyo’s Azor.”



About Formulary Advantages in Hypertension: Penetration of Advantaged Tiers by Novel Agents and Fixed-Dose Combinations

The new Formulary Forum report is based on a survey of 50 pharmacy directors who control national, regional and state-level MCOs. Answers were segmented by type of plan to illustrate variances in strategy by size of plan. The easy-to-use PowerPoint format allows users to cut-and-paste graphs and data into their own presentations.



About Formulary Forum

Formulary Forum is the first and only source for identifying the trends in formulary positioning of competing agents, understanding why those trends were taking place and predicting what changes lay ahead for brand positioning in the face of both patent expiries and new drug launches. The new report series from HealthLeaders-InterStudy combines historical formulary data from Fingertip Formulary, which maintains the highest quality and most comprehensive, integrated database of formulary information in the United States, with a robust survey of 50 MCO pharmacy directors. The pharmacy directors responses reveal what events triggered movement of key brands within their formulary for a specific disease as well as what moves they expect to make in formulary structure as new brands enter the market.



About Fingertip Formulary

Fingertip Formulary (www.FingertipFormulary.com) offers comprehensive formulary data covering commercial, Medicaid, Medicare and PBM plans, among others, in the United States. Fingertip Formulary is a Decision Resources, Inc. company.



About HealthLeaders-InterStudy

HealthLeaders-InterStudy, a Decision Resources, Inc. company, is the authoritative source for managed care data, analysis and news. For more information, please visit www.HL-ISY.com.



About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Both HealthLeaders-InterStudy and Fingertip Formulary are Decision Resources, Inc. companies. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.



All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.



a New Report from HealthLeaders-InterStudy

SOURCE HealthLeaders-InterStudy
Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
Osteotech Announces Stock Repurchase Program
S
Pharmasset Reports Fiscal Year End 2008 Financial ...